Research programme: antibody-drug conjugates - MedImmune/Seattle Genetics

Drug Profile

Research programme: antibody-drug conjugates - MedImmune/Seattle Genetics

Latest Information Update: 12 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Aug 2009 Preclinical development is ongoing in USA
  • 05 Nov 2007 MedImmune has exercised its option to obtain an exclusive license to a second antigen target under the antibody-drug congugate collaboration with Seattle Genetics
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top